Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
92 shown of 6,330 total abstracts
  1. Abstract 65422026-06-05 · 13:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-337 study)
    J. Brahmer, E. Winer, C. Robert · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  2. Abstract TPS80012026-06-05 · 19:30 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-354
    M. Reck, H. Rugo, S. Antonia · Mayo Clinic
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  3. Abstract 68692026-06-04 · 18:15 CT · E450
    Long-term follow-up of Keytruda neoadjuvant for RCC: KEYNOTE-508
    T. Mok, C. Saura, N. Rizvi · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  4. Abstract 62222026-06-02 · 15:30 CT · S100A
    KEYNOTE-167: Keytruda (pembrolizumab) maintenance in RCC
    J. Brahmer, M. Krop, E. Winer, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  5. Abstract 61072026-06-03 · 20:00 CT · S100A
    Quality of life outcomes with Keytruda in patients with RCC
    A. Spira, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  6. Abstract 69062026-06-03 · 21:15 CT · S406
    CheckMate-496: Opdivo (nivolumab) 2L in RCC
    C. Saura, J. Brahmer, N. Rizvi, et al. · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  7. Abstract 68972026-06-04 · 21:45 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with RCC
    E. Winer, S. Antonia, R. Herbst, et al. · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  8. Abstract 67792026-06-05 · 21:30 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-156
    S. Modi, M. Krop, P. Schmid · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  9. Abstract 65832026-06-01 · 18:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-781
    S. Modi, P. Schmid, S. Tolaney, et al. · Cleveland Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  10. Abstract 63712026-06-05 · 14:15 CT · E450
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-748
    M. Krop, A. Spira · Cleveland Clinic
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  11. Abstract 67152026-06-02 · 21:00 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-709
    T. Mok, A. Spira · National Cancer Center Japan
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  12. Abstract 68132026-06-01 · 19:45 CT · S100A
    Real-world effectiveness of Opdivo vs standard of care in RCC
    M. Krop, C. Saura, G. Curigliano · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  13. Abstract 69632026-06-04 · 18:30 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-841
    C. Saura, T. Mok, G. Curigliano, et al. · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  14. Abstract 62032026-06-02 · 21:00 CT · S100A
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-461
    P. Schmid, F. Andre, G. Curigliano, et al. · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  15. Abstract 66682026-06-04 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-395 study)
    C. Saura, N. Rizvi · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  16. Abstract 62772026-06-04 · 21:15 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in RCC
    S. Peters, S. Modi, S. Antonia, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  17. Abstract 65272026-06-05 · 18:00 CT · S100A
    Long-term follow-up of Keytruda 2L for RCC: KEYNOTE-620
    S. Tolaney, C. Robert, L. Paz-Ares · Mayo Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  18. Abstract 61882026-06-01 · 15:45 CT · E450
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-753
    H. Borghaei, N. Rizvi, J. Brahmer, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  19. Abstract 68712026-06-05 · 18:30 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-515
    E. Winer, A. Spira, C. Saura · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  20. Abstract LBA4019LBA2026-06-05 · 13:45 CT · S406
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-897
    S. Antonia, M. Krop, F. Andre · Massachusetts General Hospital
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  21. Abstract 66332026-06-04 · 21:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda neoadjuvant for RCC: KEYNOTE-138
    L. Paz-Ares, E. Winer · Stanford Cancer Institute
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  22. Abstract 61892026-06-02 · 21:00 CT · S406
    CheckMate-823: Opdivo (nivolumab) 2L in RCC
    L. Paz-Ares, P. Schmid, N. Rizvi, et al. · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  23. Abstract 66572026-06-03 · 21:30 CT · Arie Crown Theater
    KEYNOTE-11: Keytruda (pembrolizumab) adjuvant in RCC
    S. Peters, G. Curigliano, N. Rizvi, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  24. Abstract LBA4023LBA2026-06-04 · 14:15 CT · Hall B1
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-664
    M. Krop, F. Andre · Chinese University of Hong Kong
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  25. Abstract 69242026-06-02 · 18:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-353 study)
    T. Mok, N. Rizvi · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  26. Abstract LBA4025LBA2026-06-03 · 14:15 CT · E450
    Long-term follow-up of Opdivo adjuvant for RCC: CheckMate-440
    S. Modi, T. Mok, P. Schmid, et al. · Karolinska Institute
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  27. Abstract 62842026-06-01 · 19:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-55 study)
    C. Robert, S. Peters, J. Cortes · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  28. Abstract 67942026-06-02 · 15:15 CT · S100A
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-523
    M. Krop, L. Paz-Ares, A. Spira, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  29. Abstract 62572026-06-01 · 13:15 CT · Arie Crown Theater
    KEYNOTE-381: Keytruda (pembrolizumab) 3L+ in RCC
    S. Modi, P. Schmid, A. Spira, et al. · National Cancer Center Japan
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  30. Abstract 61872026-06-02 · 20:30 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-775
    S. Peters, L. Paz-Ares, C. Robert · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  31. Abstract 69962026-06-01 · 21:45 CT · S100A
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-449 study)
    N. Rizvi, M.C. Garassino · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  32. Abstract 68522026-06-03 · 20:15 CT · S100A
    CheckMate-683: Opdivo (nivolumab) neoadjuvant in RCC
    J. Brahmer, J. Cortes, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  33. Abstract 61712026-06-01 · 21:45 CT · S100A
    KEYNOTE-186: Keytruda (pembrolizumab) adjuvant in RCC
    P. Schmid, S. Peters, C. Robert, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  34. Abstract 64502026-06-01 · 13:30 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-471
    J. Cortes, A. Spira, S. Modi · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  35. Abstract 69792026-06-01 · 18:00 CT · Arie Crown Theater
    CheckMate-739: Opdivo (nivolumab) adjuvant in RCC
    T. Mok, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  36. Abstract 61602026-06-04 · 20:30 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-320
    C. Saura, G. Curigliano · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  37. Abstract 68412026-06-02 · 15:45 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-422
    L. Paz-Ares, E. Winer · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  38. Abstract 64182026-06-02 · 14:00 CT · Hall B1
    Long-term follow-up of Opdivo 3L+ for RCC: CheckMate-852
    G. Curigliano, A. Spira, S. Antonia, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  39. Abstract LBA4038LBA2026-06-02 · 16:00 CT · Hall B1
    KEYNOTE-7: Keytruda (pembrolizumab) neoadjuvant in RCC
    M.C. Garassino, S. Tolaney, C. Saura, et al. · Johns Hopkins Kimmel Cancer Center
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  40. Abstract 62302026-06-05 · 19:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-712
    C. Robert, F. Andre, S. Peters, et al. · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  41. Abstract 64752026-06-01 · 16:00 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-962
    S. Modi, P. Schmid, M. Reck, et al. · Stanford Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  42. Abstract 66112026-06-01 · 16:30 CT · S100A
    CheckMate-915: Opdivo (nivolumab) maintenance in RCC
    A. Spira, M.C. Garassino, M. Krop, et al. · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  43. Abstract 60862026-06-04 · 20:15 CT · Hall B1
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-917
    E. Winer, C. Robert · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  44. Abstract 61882026-06-04 · 15:45 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-728
    R. Herbst, S. Peters, S. Modi · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  45. Abstract 66812026-06-03 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-179 study)
    M.C. Garassino, S. Modi, J. Brahmer, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  46. Abstract 62522026-06-04 · 16:00 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-850
    L. Paz-Ares, C. Robert, N. Rizvi, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  47. Abstract TPS80462026-06-04 · 15:00 CT · S406
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-486
    C. Robert, G. Curigliano, S. Antonia, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  48. Abstract 69252026-06-01 · 19:30 CT · E450
    CheckMate-914: Opdivo (nivolumab) neoadjuvant in RCC
    R. Herbst, J. Brahmer · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  49. Abstract 67702026-06-01 · 13:45 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-190
    R. Herbst, E. Winer, S. Tolaney · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  50. Abstract 66752026-06-03 · 21:00 CT · S100A
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-56 study)
    T. Mok, P. Schmid · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  51. Abstract 60842026-06-04 · 13:45 CT · S406
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-620 study)
    P. Schmid, S. Tolaney · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  52. Abstract 69292026-06-05 · 14:30 CT · Hall B1
    CheckMate-948: Opdivo (nivolumab) 2L in RCC
    G. Curigliano, S. Peters, J. Brahmer, et al. · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  53. Abstract 60762026-06-02 · 21:15 CT · Hall B1
    CheckMate-839: Opdivo (nivolumab) adjuvant in RCC
    M. Krop, C. Robert · University of Chicago
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  54. Abstract 64082026-06-02 · 16:45 CT · S100A
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-12
    M. Reck, M. Krop, J. Brahmer · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  55. Abstract 60062026-06-03 · 14:00 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-591 study)
    A. Spira, S. Modi, S. Tolaney · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  56. Abstract 68312026-06-05 · 15:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-182 study)
    G. Curigliano, M. Krop · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  57. Abstract 60052026-06-02 · 20:30 CT · Hall B1
    CheckMate-558: Opdivo (nivolumab) maintenance in RCC
    T. Mok, R. Herbst, S. Peters · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  58. Abstract 69352026-06-03 · 19:15 CT · Arie Crown Theater
    KEYNOTE-598: Keytruda (pembrolizumab) 1L in RCC
    T. Mok, E. Winer, N. Rizvi, et al. · Chinese University of Hong Kong
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  59. Abstract 62792026-06-02 · 19:15 CT · E450
    CheckMate-472: Opdivo (nivolumab) 2L in RCC
    J. Cortes, A. Spira · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  60. Abstract 67892026-06-04 · 16:45 CT · Hall B1
    KEYNOTE-512: Keytruda (pembrolizumab) maintenance in RCC
    S. Antonia, P. Schmid · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  61. Abstract LBA4060LBA2026-06-05 · 21:45 CT · S406
    CheckMate-942: Opdivo (nivolumab) neoadjuvant in RCC
    H. Rugo, S. Peters, N. Rizvi, et al. · Stanford Cancer Institute
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  62. Abstract 63662026-06-03 · 13:30 CT · E450
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-465
    J. Cortes, M. Reck, H. Rugo, et al. · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  63. Abstract 69162026-06-05 · 14:45 CT · S406
    Long-term follow-up of Keytruda adjuvant for RCC: KEYNOTE-726
    S. Tolaney, S. Modi · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  64. Abstract 61702026-06-04 · 14:00 CT · S406
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-504
    F. Andre, L. Paz-Ares, C. Robert, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  65. Abstract 68422026-06-02 · 14:00 CT · S406
    Long-term follow-up of Keytruda maintenance for RCC: KEYNOTE-736
    R. Herbst, J. Cortes, M. Reck, et al. · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  66. Abstract 68952026-06-05 · 16:45 CT · E450
    CheckMate-984: Opdivo (nivolumab) neoadjuvant in RCC
    P. Schmid, F. Andre · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  67. Abstract 65912026-06-05 · 20:30 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-838 study)
    N. Rizvi, J. Brahmer · Mayo Clinic
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  68. Abstract 67922026-06-01 · 18:15 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-499
    C. Robert, H. Rugo, J. Cortes, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  69. Abstract 64782026-06-03 · 13:15 CT · E450
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-671 study)
    F. Andre, C. Saura, M.C. Garassino, et al. · Royal Marsden Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  70. Abstract TPS80692026-06-04 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-516 study)
    L. Paz-Ares, S. Peters · Memorial Sloan Kettering Cancer Center
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  71. Abstract 64922026-06-05 · 19:15 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-427
    H. Borghaei, M. Reck, P. Schmid, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  72. Abstract TPS80712026-06-05 · 18:15 CT · S100A
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-951
    J. Cortes, H. Rugo, A. Spira, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  73. Abstract 62802026-06-02 · 15:00 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-264
    F. Andre, T. Mok, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  74. Abstract 64192026-06-02 · 18:00 CT · S100A
    CheckMate-637: Opdivo (nivolumab) neoadjuvant in RCC
    N. Rizvi, S. Modi · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  75. Abstract 65972026-06-05 · 20:15 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-105
    J. Cortes, S. Tolaney, M.C. Garassino · Princess Margaret Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  76. Abstract 65462026-06-02 · 14:45 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-433 study)
    M. Krop, J. Cortes · University of Chicago
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  77. Abstract LBA4076LBA2026-06-02 · 15:00 CT · S406
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-513 study)
    H. Rugo, G. Curigliano · Mayo Clinic
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  78. Abstract 60932026-06-02 · 13:30 CT · S100A
    CheckMate-858: Opdivo (nivolumab) maintenance in RCC
    G. Curigliano, S. Tolaney, S. Peters, et al. · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  79. Abstract 66162026-06-05 · 14:15 CT · E450
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-972 study)
    G. Curigliano, N. Rizvi, H. Rugo, et al. · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  80. Abstract 65142026-06-01 · 16:45 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-941
    S. Antonia, S. Tolaney · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  81. Abstract 63452026-06-02 · 19:30 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-81
    R. Herbst, M. Krop, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  82. Abstract 67302026-06-02 · 13:45 CT · Arie Crown Theater
    Long-term follow-up of Opdivo 3L+ for RCC: CheckMate-232
    M.C. Garassino, J. Cortes · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  83. Abstract 62742026-06-01 · 18:30 CT · S406
    Long-term follow-up of Keytruda neoadjuvant for RCC: KEYNOTE-80
    S. Tolaney, L. Paz-Ares, P. Schmid, et al. · Karolinska Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  84. Abstract 63292026-06-03 · 19:45 CT · Hall B1
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-124
    S. Antonia, C. Robert, T. Mok, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  85. Abstract 69632026-06-01 · 20:30 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-337
    M.C. Garassino, F. Andre, S. Peters · Karolinska Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  86. Abstract 60122026-06-05 · 14:30 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-872 study)
    N. Rizvi, S. Modi, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  87. Abstract 67202026-06-01 · 18:30 CT · S100A
    Long-term follow-up of Opdivo maintenance for RCC: CheckMate-902
    R. Herbst, S. Peters, E. Winer, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  88. Abstract 62662026-06-02 · 13:15 CT · E450
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-460 study)
    C. Saura, R. Herbst · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  89. Abstract 69542026-06-03 · 16:45 CT · E450
    CheckMate-403: Opdivo (nivolumab) maintenance in RCC
    P. Schmid, J. Brahmer, R. Herbst, et al. · Cleveland Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  90. Abstract 66992026-06-04 · 15:30 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-494
    A. Spira, M. Krop, F. Andre · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  91. Abstract 65312026-06-03 · 15:45 CT · S100A
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-551 study)
    M. Reck, N. Rizvi, S. Tolaney, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  92. Abstract 60612026-06-01 · 15:15 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-243 study)
    C. Saura, J. Brahmer, F. Andre, et al. · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.